Vaxart (NASDAQ:VXRT) Stock Passes Below Two Hundred Day Moving Average - What's Next?

Key Points

• Vaxart's shares recently fell below their 200-day moving average of $0.44, trading as low as $0.35 before closing at $0.39 with a volume of 503,483 shares.
• Wall Street analysts have upgraded Vaxart to a "hold" rating", with a consensus recommendation of "Buy" and an average target price of $2.00.
• Institutional investors have shown increasing interest, as hedge funds collectively own about 18.05% of Vaxart's stock, with significant stakes being added by firms like Raymond James and Goldman Sachs.

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.44 and traded as low as $0.35. Vaxart shares last traded at $0.39, with a volume of 503,483 shares.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Vaxart to a "hold" rating in a report on Thursday, May 22nd. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $2.00.

Vaxart Stock Performance

The company's 50-day simple moving average is $0.38 and its two-hundred day simple moving average is $0.43. The firm has a market cap of $86.54 million, a PE ratio of -1.40 and a beta of 1.33.

Institutional Trading of Vaxart

A number of large investors have recently made changes to their positions in the stock. Bank of America Corp DE boosted its holdings in shares of Vaxart by 10.8% in the fourth quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock worth $122,000 after buying an additional 17,942 shares during the last quarter. Graham Capital Management L.P. lifted its holdings in shares of Vaxart by 155.8% in the fourth quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company's stock worth $35,000 after buying an additional 32,482 shares in the last quarter. Raymond James Financial Inc. increased its position in Vaxart by 16.9% in the second quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company's stock worth $107,000 after purchasing an additional 34,075 shares during the last quarter. Invesco Ltd. increased its position in Vaxart by 93.1% in the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 70,568 shares during the last quarter. Finally, Creative Planning bought a new position in Vaxart during the second quarter valued at $33,000. 18.05% of the stock is currently owned by institutional investors.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.